Lacey Hough
Family · Guthrie, OKNPI 1437634714
Payments from drug & device makers
Across 180 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$561
- Novo Nordisk$456
- Pfizer$371
- Lilly USA, LLC$254
- AbbVie$186
- GSK$185
- plus $720 from 19 others
What the payments were for
- Food & beverage$2,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 48 | $561 |
| Novo Nordisk | 30 | $456 |
| Pfizer | 23 | $371 |
| Lilly USA, LLC | 15 | $254 |
| AbbVie | 10 | $186 |
| GSK | 12 | $185 |
| Amarin Pharma, Inc. | 7 | $120 |
| Merck | 5 | $66 |
| Biogen | 4 | $60 |
| Mylan Specialty L.p. | 3 | $58 |
| Exact Sciences | 3 | $52 |
| Genentech USA, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| AstraZeneca(2 entities) | 2 | $31 |
| Dexcom, Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $16 |
How this compares
$2,734 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $69,101 |
| TrulicityDulaglutide | 33 | $42,478 |
| RybelsusSemaglutide | 21 | $36,725 |
| JardianceEmpagliflozin | 25 | $33,549 |
| EliquisApixaban | 26 | $25,342 |
| OzempicSemaglutide | 11 | $10,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,404 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,175 |
| Duloxetine Hcl | 48 | $1,174 |
| Atorvastatin Calcium | 87 | $1,107 |
| Omeprazole | 65 | $1,067 |
| Montelukast Sodium | 49 | $1,046 |
| Rosuvastatin Calcium | 93 | $994 |
| Fluvoxamine Maleate | 21 | $890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $185 | $69,101100 claims |
| Novo NordiskRybelsus, Ozempic | $456 | $47,41632 claims |
| Lilly USA, LLCTrulicity | $254 | $42,47833 claims |
| Boehringer IngelheimJardiance | $26 | $33,54925 claims |
| PfizerEliquis | $371 | $25,34226 claims |
| AstraZenecaBreztri Aerosphere | $31 | $10,35513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.
Other family in Guthrie
- Matthew HillisGuthrie$8K
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Brandy ReevesNorman$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.